Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients.

[1]  S. Rosenberg,et al.  Identification of Endogenous HLA-A2–Restricted Reactivity Against Shared Melanoma Antigens in Patients Using the Quantitative Real-Time Polymerase Chain Reaction , 2002, Journal of immunotherapy.

[2]  M. Perricone,et al.  Analysis of cellular immune responses in the peripheral blood of mice using real-time RT-PCR. , 2002, Journal of immunological methods.

[3]  P. Hwu,et al.  Retrovirally Transduced Human Dendritic Cells Can Generate T Cells Recognizing Multiple MHC Class I and Class II Epitopes from the Melanoma Antigen Glycoprotein 100 , 2001, The Journal of Immunology.

[4]  M. Gonzales,et al.  N‐linked carbohydrates in tyrosinase are required for its recognition by human MHC class II‐restricted CD4+ T cells , 2001, European journal of immunology.

[5]  D. Speiser,et al.  Ex Vivo IFN-γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases1 , 2001, The Journal of Immunology.

[6]  V. Engelhard,et al.  Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients , 2001, International journal of cancer.

[7]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[8]  H. Lyerly,et al.  Assays for monitoring cellular immune responses to active immunotherapy of cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Francesco M Marincola,et al.  T-cell-directed cancer vaccines: the melanoma model , 2001, Expert opinion on biological therapy.

[10]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[11]  E. Gehan,et al.  Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Kourilsky,et al.  Recombinant viruses as a tool for therapeutic vaccination against human cancers. , 2000, Immunology letters.

[13]  F. Marincola,et al.  Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. , 2000, Journal of the National Cancer Institute.

[14]  F. Marincola,et al.  Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells , 2000, The Journal of Immunology.

[15]  J. Abastado,et al.  Adenoviral transduction of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. , 2000, Journal of immunological methods.

[16]  G. Linette,et al.  In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma1 , 2000, The Journal of Immunology.

[17]  F. Marincola,et al.  Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases , 2000, The Journal of Immunology.

[18]  N. Restifo,et al.  The promise of nucleic acid vaccines , 2000, Gene Therapy.

[19]  E. Wang,et al.  Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. , 1999, Journal of immunology.

[20]  S. Rosenberg,et al.  MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. , 1999, Cancer research.

[21]  R. K. Bright,et al.  Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells. , 1999, Journal of immunology.

[22]  S. Rosenberg,et al.  Human tumor antigens for cancer vaccine development , 1999, Immunological reviews.

[23]  J. Kaplan,et al.  Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. , 1999, Journal of immunology.

[24]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[25]  K. Sakaguchi,et al.  Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. , 1998, Journal of immunology.

[26]  D. Morton,et al.  Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. , 1998, Seminars in surgical oncology.

[27]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[28]  J. Shabanowitz,et al.  Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. , 1998, Journal of immunology.

[29]  A Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.

[30]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[31]  K. Sakaguchi,et al.  Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. , 1995, Journal of immunology.

[32]  S. Rosenberg,et al.  Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. , 1994, Cancer research.